Low-dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis (LVP) in Decompensated Cirrhosis Liver.
Key facts
- Who runs it
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 52 people enrolled
- Started
- 2 Feb 2024
- Ended
- 28 Feb 2025
- Type of study
- InterventionalOne group gets an existing treatment, for comparison.
- Treatments tested
- Albumin infusion, 2g/L of ascitic fluid aspiration.
- Record updated
- 24 March 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Other criteria
- Inclusion criteria:; Cirrhotic patients with grade-III ascites; Age 18 to 80 years; Willing to consent for clinical trial
- Exclusion criteria:; Acute liver failure; Impaired consciousness; Patients with following concomitant diseases,; Severe cardiac diseases, respiratory diseases, and Renal impairment, (S. Creatinine >1.5 mg/dl); Hyponatremia; Advanced HCC (>3 nodule, portal vein thrombosis); Hepatic encephalopathy,; Sepsis,; Recent bleeding, e.g., GIT hemorrhage within 7 days before study; Pregnancy; Unable or not willing to consent for clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Abstract for thesis protocol. Background: Paracentesis induced circulatory dysfunction (PICD) is a common complication of large volume paracentesis in cirrhotic patients, which can lead to renal impairment, hyponatremia, and increased mortality. Albumin infusion is recommended to prevent PICD, but the optimal dose is unclear. We aim to compare the efficacy of low dose albumin infusion versus standard dose of albumin in preventing PICD in cirrhotic patients.
Read full original descriptionShow less
Material and methods: We will conduct a randomized controlled trial with two arms: low dose albumin infusion (2g per liter of ascitic fluid removed) versus standard dose albumin infusion (6g per liter of ascitic fluid removed). Patients with liver cirrhosis undergoing large volume paracentesis (>5 L) with serum creatinine <1.5 mg/dL and no signs of infection will be included in the study.
Sample size calculation: Based on previous studies, group sample size will be 26 and will achieve 80.749% power to reject null hypothesis. As per availability, 30 participants will be included in each group, with a total number of 60 for this trial.
Outcome of the study:
The primary outcome is the incidence of paracentesis induced circulatory dysfunction (PICD) in both groups, (Low dose albumin and standard dose of albumin), 7 days after paracentesis.
The secondary outcomes are renal failure, hyponatremia, hepatic encephalopathy, hepatorenal syndrome, and length of hospital stay.
Conclusion: This trial will provide evidence on whether low dose albumin infusion is as effective as standard dose albumin infusion in preventing PICD in cirrhotic patients. This could have implications for reducing the cost and optimal effective dose of albumin therapy, as well as improving the outcomes of patients with ascites.
The group in the trial
- Albumin infusion, 6gm/L of ascitic fluid aspiration.Existing treatment, for comparison
Treatment: Albumin infusion, 2g/L of ascitic fluid aspiration.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Low-Dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis in Decompensated Cirrhosis of Liver.
- Record updated
- 24 March 2025